Krystal Biotech Inc (KRYS NASDAQ) stock market data APIs
$152.83
-0.63(-0.4%)
as of January 22, 2025
Krystal Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Prev. Close
153.46
Open
152.83
Volume
241 K
High
153.74
Low
150.985
52 wk Range
107.5-219.34
Market Cap
4 414 M
P/E Ratio
86.2135
Shares Outstanding
28 761 K
Revenue
242 M
EPS
0.91
Beta
0.82
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 242 M
- EBITDA: 69 145 K
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-04
- EPS/Forecast: 0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News
New
US Growth Companies With High Insider Ownership In January 2025
As the U.S. markets continue to rally, buoyed by President Trump's recent executive actions and a positive economic outlook, investors are increasingly focused on growth companies with solid fundament...
High Growth Tech Stocks to Watch in January 2025
Over the last week, the United States market saw a 3.1% increase, contributing to a 24% climb over the past year, with earnings forecasted to grow by 15% annually. In this environment of robust growth...
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Krystal Biotech, Inc. PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging ...
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth
As the U.S. stock market inches higher in a holiday-shortened session, with indices like the Nasdaq Composite and S&P 500 posting modest gains, investors are keeping a close eye on growth stocks that ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
